ED90 for Hyperbaric Bupivacaine in Super Obese Parturients
Primary Purpose
Obesity, Morbid, Spinal Anesthesia, Cesarean Delivery
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Bupivacaine
Sponsored by
About this trial
This is an interventional treatment trial for Obesity, Morbid focused on measuring Bupivacaine ED90, Cesarean Delivery, Obesity, Spinal Anesthesia
Eligibility Criteria
Inclusion Criteria:
- American Society of Anesthesiology (ASA) class 2 and 3
- English speaking
- Gestational age > 36 weeks
- Scheduled for cesarean delivery under combined spinal epidural anesthesia
- 18 years or older
- BMI > 50 kg/m2
Exclusion Criteria:
- History of past or current intravenous drug or chronic opioid abuse
- Allergy or contraindication to any study medications
- Intrapartum cesarean delivery under epidural anesthesia
- Cesarean delivery under general anesthesia
Sites / Locations
- Duke University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Starting dose of Bupivacaine (9 mg)
Subsequent dose
Arm Description
The starting dose of hyperbaric bupivacaine for the first patient in this study will be 9mg; the dose for the subsequent subject will be based on the response of the preceding subject as per the Narayana Rule, a modification of the biased-coin design (BCD) up-down sequential method (UDM).
Outcomes
Primary Outcome Measures
Percent of successful blocks for induction (success induction)
bilateral T6 sensory level to pinprick by
Percent of successful blocks for operation (success operation)
successful initial sensory level without requiring additional epidural anesthetic
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03781388
Brief Title
ED90 for Hyperbaric Bupivacaine in Super Obese Parturients
Official Title
ED90 for Hyperbaric Bupivacaine in Spinal Anesthesia for Cesarean Delivery in Super Obese Parturients
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
May 1, 2019 (Actual)
Primary Completion Date
December 6, 2022 (Actual)
Study Completion Date
December 6, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study is to determine the ED90 of hyperbaric intrathecal bupivacaine for the super obese population undergoing cesarean section under a combined spinal epidural technique.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Morbid, Spinal Anesthesia, Cesarean Delivery
Keywords
Bupivacaine ED90, Cesarean Delivery, Obesity, Spinal Anesthesia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Sequential Assignment
Model Description
The starting dose of hyperbaric bupivacaine for the first patient in this study will be 9mg; the dose for the subsequent subject will be based on the response of the preceding subject as per the Narayana Rule, a modification of the biased-coin design (BCD) up-down sequential method (UDM).
Masking
ParticipantCare ProviderOutcomes Assessor
Masking Description
Blinded study drugs will be prepared by an anesthesia provider not involved in the study. The anesthesia provider providing care to the patient will be blinded to the dosage of the hyperbaric bupivacaine. In order to preserve the blinding of the provider, the total volume of study drug will be maintained at a constant of 2.05mL. The difference in total volume based on the variation of hyperbaric bupivacaine dosing will be replaced with preservative free normal saline.
Allocation
Non-Randomized
Enrollment
45 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Starting dose of Bupivacaine (9 mg)
Arm Type
Experimental
Arm Description
The starting dose of hyperbaric bupivacaine for the first patient in this study will be 9mg; the dose for the subsequent subject will be based on the response of the preceding subject as per the Narayana Rule, a modification of the biased-coin design (BCD) up-down sequential method (UDM).
Arm Title
Subsequent dose
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Bupivacaine
Intervention Description
Determination of the dose will rely on the outcomes of the preceding 7 patients receiving the same dose, as the number of previous patients to consider is a function of the target dose. Among all patients who received a certain dose, a proportion of successful outcomes will be determined (P(d)); if P(d) <0.90, and at least one of the previous 7 patients who received the same dose had an unsatisfactory outcome, the next patient will receive a pre-determined increment of 0.75 mg of bupivacaine. Alternatively, if P(d) 0.90 and the previous 7 patients who received the same dose had successful outcomes, the next patient will receive a pre-determined decrement of 0.75mg of bupivacaine. Otherwise, the dose will remain the same.
Primary Outcome Measure Information:
Title
Percent of successful blocks for induction (success induction)
Description
bilateral T6 sensory level to pinprick by
Time Frame
10 minutes after intrathecal drug administration
Title
Percent of successful blocks for operation (success operation)
Description
successful initial sensory level without requiring additional epidural anesthetic
Time Frame
during surgery up to 90 minutes after intrathecal injection
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
American Society of Anesthesiology (ASA) class 2 and 3
English speaking
Gestational age > 36 weeks
Scheduled for cesarean delivery under combined spinal epidural anesthesia
18 years or older
BMI > 50 kg/m2
Exclusion Criteria:
History of past or current intravenous drug or chronic opioid abuse
Allergy or contraindication to any study medications
Intrapartum cesarean delivery under epidural anesthesia
Cesarean delivery under general anesthesia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ashraf S Habib, MD
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke University Hospital
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
ED90 for Hyperbaric Bupivacaine in Super Obese Parturients
We'll reach out to this number within 24 hrs